Applications of iPSC-derived beta cells from patients with diabetes

Cell Reports Medicine

Jeffrey R. Millman¹  Kristina G. Maxwell² 

[1] Department of Biomedical Engineering, Washington University in St. Louis, St. Louis, MO 63130, USA;Division of Endocrinology, Metabolism, and Lipid Research, Washington University School of Medicine, St. Louis, MO 63110, USA;

关键词: diabetes;    stem cells;    differentiation;    disease modeling;    cell therapy;    CRISPR;   

DOI  :  

来源: DOAJ

【 摘 要 】

Summary: Improved stem cell-derived pancreatic islet (SC-islet) differentiation protocols robustly generate insulin-secreting β cells from patient induced pluripotent stem cells (iPSCs). These advances are enabling in vitro disease modeling studies and the development of an autologous diabetes cell replacement therapy. SC-islet technology elucidates key features of human pancreas development and diabetes disease progression through the generation of pancreatic progenitors, endocrine progenitors, and β cells derived from diabetic and nondiabetic iPSCs. Combining disease modeling with gene editing and next-generation sequencing reveals the impact of diabetes-causing mutations and diabetic phenotypes on multiple islet cell types. In addition, the supply of SC-islets, containing β and other islet cell types, is unlimited, presenting an opportunity for personalized medicine and overcoming several disadvantages posed by donor islets. This review highlights relevant studies involving iPSC-β cells and progenitors, encompassing new conclusions involving cells from patients with diabetes and the therapeutic potential of iPSC-β cells.

【 授权许可】

Unknown